Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07307911
PHASE2

Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy

Sponsor: Damanhour University

View on ClinicalTrials.gov

Summary

* This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are: * Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy? * How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment? * Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks. * Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle. * Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.

Official title: Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropathy

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-11-10

Completion Date

2026-02-10

Last Updated

2026-04-08

Healthy Volunteers

Yes

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q 10

Coenzyme Q10 200 mg orally twice daily for twelve weeks, for CoQ 10 grpup only

DRUG

Paclitaxel

: Paclitaxel 80 mg/m² administered weekly for twelve weeks to Control and CoQ groups

Locations (1)

Damanhur Oncology Center

Damanhūr, Egypt